Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

In the last 5 years, FDA has actively characterized innovative ECG analysis methods for proarrhythmia assessments in clinical trials. ECG is a cornerstone of cardiac safety monitoring in toxicology and safety pharmacology with similarities between clinical and non-clinical evaluations.

A presentation was given by CitoxLab North America during SOT Annual Meeting & ToxExpo 2019, in Baltimore:

Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

 

Other posts you may like

Software solution with SEND compatible outputs

Discover how emka helps you to comply with regulatory guidance

SOT 59th Annual Meeting and ToxExpo

Wednesday March 18th, 2020 Anaheim, CA - USA

Happy Holidays from all of us at emka TECHNOLOGIES

Please take note that our offices will be closed during holidays. Consult the dates here.

Pharmacology 2019

December 15-17, 201 Edinburgh, UK Booth #14